{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunoglobulin+Disease&page=4", "query": { "condition": "Immunoglobulin Disease", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 2538, "total_pages": 254, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunoglobulin+Disease&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunoglobulin+Disease&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T10:32:46.331Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03329950", "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Breast Cancer", "Gastric Cancer", "Renal Cell Carcinoma", "Ovarian Cancer", "Cholangiocarcinoma", "Bladder Urothelial Carcinoma", "Pancreatic Adenocarcinoma", "Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Head and Neck Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Other Solid Tumors", "Diffuse Large B-cell Lymphoma (DLBCL)", "Mantle Cell Lymphoma", "Indolent B-cell Lymphomas", "Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Waldenstrom's Disease", "Marginal Zone Lymphoma", "Mucosa Associated Lymphoid Tissue", "Small Lymphocytic Leukemia" ], "interventions": [ { "name": "CDX-1140", "type": "DRUG" }, { "name": "CDX-301", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2017-12-01", "completion_date": "2022-09-13", "has_results": false, "last_update_posted_date": "2024-03-28", "last_synced_at": "2026-10-06T10:32:46.331Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03329950" }, { "nct_id": "NCT00538668", "title": "Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "117Lu-J591", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "85 Years", "sex": "MALE", "summary": "21 Years to 85 Years · Male only" }, "enrollment_count": 55, "start_date": "2007-08", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2021-03-19", "last_synced_at": "2026-10-06T10:32:46.331Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538668" }, { "nct_id": "NCT00338650", "title": "Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1000, "start_date": "2006-06", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2007-11-29", "last_synced_at": "2026-10-06T10:32:46.331Z", "location_count": 97, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 74 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Roseville", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00338650" }, { "nct_id": "NCT00001865", "title": "HAT in Eye Complications of Behcet's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Behcet's Syndrome", "Retinal Disease", "Uveitis" ], "interventions": [ { "name": "Daclizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 26, "start_date": "1999-07", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-06T10:32:46.331Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001865" }, { "nct_id": "NCT00266565", "title": "Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hypereosinophilic Syndromes", "Eosinophilic Gastroenteritis", "Churg-Strauss Syndrome", "Eosinophilic Esophagitis" ], "interventions": [ { "name": "Mepolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2001-12", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2020-07-29", "last_synced_at": "2026-10-06T10:32:46.331Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00266565" }, { "nct_id": "NCT00142181", "title": "Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoplasmacytic Lymphoma", "Waldenstrom's Macroglobulinemia" ], "interventions": [ { "name": "Campath-1H", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 27, "start_date": "2003-03", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2012-12-21", "last_synced_at": "2026-10-06T10:32:46.331Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00142181" }, { "nct_id": "NCT04084665", "title": "Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Guselkumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2020-06-01", "completion_date": "2020-07-30", "has_results": false, "last_update_posted_date": "2020-06-05", "last_synced_at": "2026-10-06T10:32:46.331Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04084665" }, { "nct_id": "NCT03168100", "title": "2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2017-10-01", "completion_date": "2019-01-24", "has_results": false, "last_update_posted_date": "2019-01-28", "last_synced_at": "2026-10-06T10:32:46.331Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03168100" }, { "nct_id": "NCT04448834", "title": "Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dorothy Sipkins, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-01", "completion_date": "2023-06-01", "has_results": false, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-10-06T10:32:46.331Z", "location_count": 3, "location_summary": "Tampa, Florida • Durham, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04448834" }, { "nct_id": "NCT05683834", "title": "Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epstein-Barr Virus Infection", "Infectious Mononucleosis", "Herpesvirus" ], "interventions": [ { "name": "Matrix-M1 Adjuvant", "type": "DRUG" }, { "name": "EBV gp350-Ferritin Vaccine", "type": "DRUG" }, { "name": "Placebo Comparator", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "18 Years to 25 Years" }, "enrollment_count": 25, "start_date": "2023-09-22", "completion_date": "2026-04-20", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-06T10:32:46.331Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05683834" } ] }